Study of budiodarone for atrial fibrillation
Part of Heart & circulation clinical trials.
This study tests a new medicine, budiodarone, to help control atrial fibrillation (an irregular heartbeat) in people who haven't been helped by other treatments. It may reduce the time spent in AF and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation that comes and goes (paroxysmal) or is persistent and you are scheduled for your first or second electrical cardioversion (a procedure to restore normal heart rhythm).
- During a 28-day monitoring period, you must have atrial fibrillation more than 5% of the time and meet certain patterns of episodes (for example, at least two episodes lasting 5 hours or more, or similar).
- You have already tried at least one treatment for atrial fibrillation that didn't work well.
- Your atrial fibrillation symptom score (AFSS) is greater than 3 (meaning you have noticeable symptoms).
- Your stroke risk score (CHA₂DS₂-VASc) is 1 or more for men and 2 or more for women, and you are on a blood thinner for at least 3 weeks before starting the study medicine.
- If you have heart failure, it must be mild (NYHA class I or II).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares three different daily doses of the heart rhythm medication amiodarone to find the most effective one for preventing episodes of paroxysmal atrial fibrillation. Participants will take one of three doses (100, 200, or 400 mg) for up to 12 months, and the study will monitor how well each dose controls the irregular heartbeat.
This study compares different heart rate targets for people with ongoing atrial fibrillation (an irregular heartbeat) to find which one improves symptoms and quality of life. It may help you and your doctor choose the best treatment plan.
This study tests whether giving the medicine amiodarone before a scheduled electrical cardioversion (a procedure that shocks the heart back into rhythm) improves the chances of restoring a normal heartbeat in people with persistent atrial fibrillation. It compares outcomes with and without this pre-treatment.
This study tests whether the medication dronedarone can help people with early atrial fibrillation (an irregular heartbeat) get back to a normal rhythm. It may help reduce symptoms and improve long-term heart health.
This study tests a new medication, AP31969, to control heart rhythm in people with atrial fibrillation. It compares the drug to a placebo to see if it can reduce how often AF episodes happen over time.
This study tests a modified 'pills-in-the-pocket' approach—taking antiarrhythmic drugs only when symptoms occur—for people with non-valvular atrial fibrillation (AF) who still have arrhythmias lasting over 24 hours after their first catheter ablation. It aims to see if this strategy can safely control symptoms without needing daily medication.
Hear when a new Paroxysmal AF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.